{"clinical_study": {"@rank": "230", "required_header": {"download_date": "ClinicalTrials.gov processed this data on April 06, 2020", "link_text": "Link to the current ClinicalTrials.gov record.", "url": "https://clinicaltrials.gov/show/NCT04331886"}, "id_info": {"org_study_id": "TARGET-COVID-19", "nct_id": "NCT04331886"}, "brief_title": "An Observational Study of Patients With Coronavirus Disease 2019", "acronym": "COVID-19", "official_title": "An Observational Study of Patients With Coronavirus Disease 2019", "sponsors": {"lead_sponsor": {"agency": "Target PharmaSolutions, Inc.", "agency_class": "Industry"}}, "source": "Target PharmaSolutions, Inc.", "oversight_info": {"has_dmc": "No", "is_fda_regulated_drug": "No", "is_fda_regulated_device": "No"}, "brief_summary": {"textblock": "This is an observational study of patients with COVID-19 designed to specifically address\n      important clinical questions that remain incompletely answered for coronavirus disease 2019."}, "detailed_description": {"textblock": "Data from up to 5,000 adult patients in the US will be captured from eligible patients\n      enrolled following admission to the hospital. Participants will have de-identified medical\n      records collected from hospital admission to discharge, including but not limited to critical\n      care monitoring, details on mechanical ventilation, laboratory data, imaging reports,\n      medications, and all procedures. Diagnosis and patient management will follow each hospital's\n      standard of care and no specific treatments, procedures or laboratory tests will be dictated\n      by enrollment in TARGET-COVID-19."}, "overall_status": "Not yet recruiting", "start_date": {"@type": "Anticipated", "#text": "April 2020"}, "completion_date": {"@type": "Anticipated", "#text": "March 2021"}, "primary_completion_date": {"@type": "Anticipated", "#text": "March 2021"}, "study_type": "Observational", "has_expanded_access": "No", "study_design_info": {"observational_model": "Cohort", "time_perspective": "Other"}, "primary_outcome": [{"measure": "Natural history of COVID-19: Characteristics of COVID-19", "time_frame": "12 months"}, {"measure": "Natural history of COVID-19: Participant demographics", "time_frame": "12 months"}, {"measure": "Natural history of COVID-19: Treatment use", "time_frame": "12 months"}, {"measure": "Time point of clinical response", "time_frame": "12 months"}], "enrollment": {"@type": "Anticipated", "#text": "5000"}, "condition": ["COVID-19", "Coronavirus"], "eligibility": {"study_pop": {"textblock": "Adults and children who are or have been hospitalized for diagnosed or suspected\n        Coronavirus (SARS-CoV-2) infection"}, "sampling_method": "Non-Probability Sample", "criteria": {"textblock": "Inclusion Criteria:\n\n          -  Adults (age \u226518 years) who are or have been hospitalized and diagnosed with Severe\n             Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) infection.\n\n          -  SARS-CoV-2 confirmed diagnosis (e.g. polymerase chain reaction [PCR] or other\n             clinically utilized test).\n\n        Exclusion Criteria:\n\n        N/A"}, "gender": "All", "minimum_age": "N/A", "maximum_age": "N/A", "healthy_volunteers": "No"}, "overall_contact": {"last_name": "Chuck Moser", "phone": "984-234-0268", "email": "cmoser@targetpharmasolutions.com"}, "verification_date": "March 2020", "study_first_submitted": "March 31, 2020", "study_first_submitted_qc": "April 1, 2020", "study_first_posted": {"@type": "Actual", "#text": "April 2, 2020"}, "last_update_submitted": "April 1, 2020", "last_update_submitted_qc": "April 1, 2020", "last_update_posted": {"@type": "Actual", "#text": "April 2, 2020"}, "responsible_party": {"responsible_party_type": "Sponsor"}, "condition_browse": {"mesh_term": "Coronavirus Infections"}}}